The molecule is too long? Or too complicated? In any way something went wrong with the molecule!
Eyebrows have been raised after Astellas Pharma decided to end its
collaboration with Ambit Biosciences Corp to develop the latter's acute myeloid
leukaemia treatment quizartinib.
Back in 2009, the companies entered into a collaboration focusing on FMS-like
tyrosine kinase-3 (FLT-3) inhibitors, including quizartinib. Now, the Japanese
drugmaker has exercised its right to terminate the agreement, citing "strategic
reasons", effective September 3, 2013.
No comments:
Post a Comment